Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Sponsor: National Cancer Institute (NCI)
Listed as NCT03373760, this PHASE2 trial focuses on Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma AJCC v7 and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 12 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
-
May 2023 — Jul 2023 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Jun 2022 — May 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
-
Jun 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jan 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jan 2019 [monthly]
Recruiting PHASE2
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .